The first European Bank for induced pluripotent Stem Cells
Welcome to the official website of EBiSC, a large European public-private partnership project supported jointly by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), which aims at establishing the first European Bank for induced pluripotent Stem Cells (iPSC).
EBiSC is designed to address the increasing demand for quality-controlled, disease-relevant research-grade iPSC lines, data and cell services.
EBiSC will demonstrate after 3 years an operational responsible banking and distribution service of iPSC lines by building a robust, reliable supply chain from the generation of cell lines, over the specification, to internationally accepted quality criteria and their world-wide distribution to any qualified user.
EBiSC will subsequently establish for Europe a centralised, not-for-profit bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.
EBiSC is coordinated by Pfizer Ltd and managed by Roslin Cells Ltd. and includes private corporations such as pharmaceutical companies, small and medium-sized enterprises (SMEs) and non-profit organisations, as well as academic, charitable and public institutions.